Perspective
Published on 23 Feb 2023
Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1063144
- 10,478 views
- 19 citations




